C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | New England Journal of Medicine |
| MU Faculty or unit | |
| Citation | |
| Web | http://dx.doi.org/10.1056/NEJMc1910394 |
| Doi | http://dx.doi.org/10.1056/NEJMc1910394 |
| Keywords | Achondroplasia; C-type natriuretic peptide |
| Description | Savarirayan et al. (July 4 issue)1 report increased skeletal growth in patients with achondroplasia (a common type of dwarfism caused by activating mutations in the tyrosine kinase fibroblast growth factor receptor 3 gene FGFR3) who received vosoritide, a stable analogue of C-type natriuretic peptide. Their study is a breakthrough in treatment for achondroplasia, and it offers an intriguing possibility of broader clinical applications. |
| Related projects: |